Status:
COMPLETED
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
Lead Sponsor:
Sanofi
Conditions:
Colorectal Neoplasms
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study. Secondary objectives include the evaluation of overall objective respo...
Eligibility Criteria
Inclusion
- Histologically proven adenocarcinoma of the colon or the rectum
- Metastatic disease not amenable to potentially curative treatment
Exclusion
- Prior therapy for metastatic cancer of the colon or the rectum
- Prior treatment with angiogenesis inhibitors
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT00851084
Start Date
February 1 2009
End Date
January 1 2012
Last Update
June 7 2016
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Investigational Site Number 036004
Douglas, Australia, 4814
2
Sanofi-Aventis Investigational Site Number 036001
Hunter Region Mail Centre, Australia, 2310
3
Sanofi-Aventis Investigational Site Number 036003
Hunter Region Mail Centre, Australia, 2310
4
Sanofi-Aventis Investigational Site Number 276003
Berlin, Germany, 13353